AAAGCTTTGTAAGTAA-3. 109
Expression and Purification of SaFabH and EcFabH. Expression strains were cultured in 110 LB medium until A 600 reached 0.6 and isopropyl-1-thio--D-galactopyranoside (IPTG) was added 111 to a final concentration of 1 mM. Cells were incubated with shaking at 16C for 18 hours. 112
Soluble proteins were applied to Ni-NTA agarose column and washed with increasing 113 concentrations of imidazole. FabH eluted with 400 mM imidazole and was subsequently applied 114 to a chitin agarose column to remove contaminating SlyD protein. The flow through from the 115 chitin column was further purified by separation on a Superdex S200 column (Amersham 116 Biosciences) equilibrated and eluted with 20 mM Tris-HCl pH 7.5, 0.1 M NaCl, 3 mM 117 dithiothreitol (DTT), 3 mM EDTA and 10% glycerol. EcFabH was expressed in BL21(DE3) and 118 purified as described previously (30) . 119
Expression and Purification of SaFabF. The expression strain was inoculated in LB 120 medium and grown to A 600 = 0.6. The flask was heat-shocked at 42C for 20 minutes before the 121 addition of 1 mM IPTG and growth at 25C for 3 hours. The cells were harvested by 122 centrifugation and resuspended in lysis buffer (20 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 10% 123 glycerol and 2 mM Tris(2-carboxyethyl)phosphine)) and lysed. After centrifugation to remove 124 debris, the supernatant was applied to Ni-NTA agarose. After elution from the column, FabF 125 was purified further using a Superdex S200 column equilibrated in 20 mM Tris-HCl pH 7.5, 1 126 mM EDTA and 1 mM DTT. 127
Synthesis of acyl-ACP thioesters. Lauryl-ACP was synthesized using V. harveyii acyl-128 ACP synthetase and S. aureus ACP (5, 31). Malonyl-ACP was synthesized using S. 129 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from pneumoniae AcpS (32, 33). Products were purified from reactions by anion exchange 130 chromatography and dialyzed overnight against 20 mM bis-Tris, pH 6.8. 131
FabH radiochemical assay. S. aureus apoACP was expressed, purified and converted to 132 ACP as described previously (33). FabH was assayed in a reaction mixture containing 50 M 133 malonyl-ACP, 50 M isobutyryl-CoA, 0.1 l [2- concentration. Assays were initiated by the addition of 37.5 ng of SaFabF and reactions were 144 incubated at 37C for 20 minutes. Samples were processed as described previously (19) . 145 LC-MS/MS of cerulenin treated FabH. Two reactions were prepared to examine the 146 covalent modification of FabH by cerulenin. Reaction 1 contained 43 mM FabH, 66 mM sodium 147 phosphate pH 7.0 and 0.5 l DMSO. Reaction 2 contained the same components but 0.5 l of 148 447 mM cerulenin instead of DMSO (7.45 mM total cerulenin concentration). Reactions were 149 incubated at 37C for one hour before the addition of 1 l of 1 M DTT. Reactions were allowed 150 to incubate for a further 20 minutes before the addition of 1 l of 600 mM iodoacetamide and a 151 second incubation at 37C for 20 minutes. Finally, excess iodoacetamide was quenched 152 through the addition of 3 l of 1 M DTT and incubating the reaction at 37 °C for 20 minutes. 153
The protein sample was digested with trypsin and mass spectrometric analysis was performed 154 using an Orbitrap Mass Spectrometer from Thermo Electron (San Jose, CA) by the St. Jude 155 Proteomics Core Facility. The digest was introduced into the instrument via on line 156 chromatography using reverse phase (C18) ultra-high pressure liquid chromatography on the 157 nanoAcquity (Waters, MA). Data acquisition involved acquiring the peptide mass (MS) spectra 158 followed by fragmentation of the peptide to produce MS/MS spectra that provides information 159 about the peptide sequence. Database searches were performed using raw files in combination 160 with the Mascot search engine. Protein/peptide assignments are made on the basis of MS/MS 161
spectra. 162
Anti-FabH and anti-FabF immunoblot. FabF and FabH polyclonal antibodies were 163 generated by Rockland Immunochemicals using the whole protein as an antigen. Cultures of 164 the specified strains were grown to A 600 = 1.0 and harvested by centrifugation at 4000 x g for 10 165
minutes. Pellets were resuspended in 100l of phosphate buffered saline pH 7.5 (PBS) 166 containing 1x Roche EDTA free protease inhibitors, 1 mg/ml lysostaphin and 0.1 mg/ml DNase 167 I. Cell suspensions were incubated on ice for 3 hours and centrifuged at 20,000 x g for 10 168
minutes. The supernatant was removed and protein quantified by Bradford assay. Samples 169 were normalized by protein concentration and boiled with 1x Laemmli sample buffer before 170 separation by SDS-PAGE. Proteins were transferred to PVDF membrane and blocked 171 overnight in Tris-buffered saline containing 5% milk with 0.1% Triton X-100 (TBSTM). The 172 primary antibody (anti-FabF or anti-FabH antisera) was added at a 1:200 dilution in TBSTM and 173 incubated for one hour. After washing 3 x 15 minutes, the secondary antibody (Goat anti-rabbit 174 alkaline phosphatase) was added at a 1:5000 dilution and incubated for one hour. After a final 175 wash, the membrane was imaged using the Typhoon 9200 PhosphoImager and electrochemical 176 fluorescence substrate (GE Healthcare). 
RESULTS

195
Mutations in fabH confer resistance to FabF-directed antibiotics. S. aureus strain 196 RN4220 (2 x 10 9 cells) was applied to LB plates containing 4 g/ml platensimycin, 4 g/ml 197 platencin, 100 g/ml thiolactomycin or 250 g/ml cerulenin and were allowed to grow for 48 198 hours. Colonies (2-3 per plate) appeared with each compound used except cerulenin. We 199 anticipated that each clone would have a missense mutation in fabF that would selectively 200 confer resistance to the antibiotic used in the selection. However, DNA sequencing of the fabF 201 genes in these resistant clones showed no mutations in the target gene, but rather each clone 202 harbored a missense mutation in the fabH gene that resulted in a modified FabH protein ( Table  203 3). In total, 15 different mutations in fabH were identified, and 5 of them were obtained more 204 (Table 3) and each mutant was equally resistant to thiolactomycin, platensimycin or platencin 206 regardless of which compound was used to select for resistance. The isolates were only 207 resistant to the FabF-targeted antibiotics. The MIC of the parent and mutant strains MWF55, 208 MWF61 and MWF64 (Table 1) were determined for AFN-1252 (3.9 ng/ml), a FASII inhibitor at 209 the FabI step; rifampicin (7.8 ng/ml), a RNA synthesis inhibitor; amoxicillin (156 ng/ml), a cell 210 wall synthesis inhibitor; clarithromycin (625 ng/ml), a protein synthesis inhibitor; and levofloxacin 211 (156 ng/ml), a DNA synthesis inhibitor. There was no difference between the MIC for the wild-212 type strain RN4220 and any of the three mutant strains for these antibiotics. The simple idea 213 that these FabF inhibitors actually block FabH in S. aureus was tested by the biochemical 214 analysis of FabH and FabF inhibition by these antibiotics in vitro. As reported by others (6, 16, 215
19, 22), they were selective FabF inhibitors. 216
Cerulenin-resistant strains were not isolated. Cerulenin is a fungal epoxide that 217 irreversibly inhibits the elongation condensing enzymes (FabF) by covalent modification of the 218 active site cysteine (37). Thus cerulenin was a natural product that was included in our screen; 219 however, repeated attempts to isolate cerulenin-resistant S. aureus mutants failed. This was a 220 frustrating outcome in light of the prior isolation of a cerulenin-resistant B. subtilis strain 221 harboring a missense mutation that produced a FabF(I108F) mutant (24). Cerulenin differs from 222 the other inhibitors in this study in that it binds to the free enzyme and not the acyl-enzyme 223 intermediate. There are many reports describing cerulenin as a selective inhibitor of FabF with 224 a much lower affinity for FabH (19, 38-40). To address this issue, we tested the potency of 225 cerulenin in a SaFabF and SaFabH enzyme assays. The IC 50 of cerulenin against S. aureus 226 FabF (SaFabF) was 17 M, consistent with a previously reported value of 22 M (40). 227
Cerulenin had a low affinity in the standard FabH assay, but when SaFabH and cerulenin were 228 incubated for 15-60 minutes before addition of the substrates, cerulenin effectively blocked 229
SaFabH activity up to 95% (Fig. 2A) (Fig. 2B) . Cerulenin-treated SaFabH was subjected to MALDI-TOF 236 MS/MS to determine if the inhibitory mechanism against SaFabH also functions by covalent 237 modification of the catalytic cysteine. A mass of 223 was attached to the catalytic Cys112 in 238
SaFabH, which corresponded to the loss of a proton and the addition of cerulenin, providing 239 convincing evidence that cerulenin is an irreversible inhibitor of SaFabH (Fig. 2C) . Cerulenin as 240 a dual inhibitor explains the inability to isolate cerulenin-resistant mutants using our approach 241 because mutations would be required in both the fabH and fabF genes. An explanation for the 242 isolation of a cerulenin-resistant mutant in in B. subtilis FabF (24, 41) was that B. subtilis 243 expresses two redundant FabH enzymes (42), whereas S. aureus has only one. 244
The FabH mutants were catalytically defective. The growth rates of strains harboring five 245 of the most frequently occurring fabH mutations were determined (Fig. 3A) . Each of these 246 mutant strains grew significantly slower than the wild-type parent. In all cases, the growth 247 defect was overcome by adding fatty acids to the growth medium (Fig. 3B) . These data 248 suggested that the reduced growth rate was due to a reduction in the rate of fatty acid synthesis 249 that arose from defects in the FabH enzyme. All of the mutations except one resulted in an 250 alteration in the fabH coding sequence. The other mutation was a G to A transformation that 251 was predicted to occur in the ribosome binding site for fabH translation. The FabH mutations 252 were mapped onto a published structure of SaFabH (43) (Fig. 4) . The mutations clustered in 253 and around the substrate binding tunnel. Several mutations were in residues directly interacting 254 with the acyl-CoA substrate, either in the tunnel accommodating the acyl-phosphopantetheine 255 moiety or in Trp32, a residue that stacks with the adenine of CoA (Fig. 4) . FabH(G203S), the 256 most frequent mutant identified in the screen, was purified. FabH(G203S) had a 10-fold 257 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from decrease in FabH specific activity (1.38 ± 0.06 mol/min/mg FabH(G203S) vs 17.3 ± 0.90 258 mol/min/mg for wild-type) illustrating that the mutant FabH(G203S) was catalytically defective. 259
The apparent Km for isobutyryl-CoA was reduced from 30.4 ± 2.0 M in wild-type to 4.6 ± 0.61 260 M in FabH(G203S), whereas the Km for malonyl-ACP increased from 10.7 ± 0.86 M in wild-261 type to 31.5 ± 2.7 M in FabH(G203S). We also purified FabH(W32C) and FabH(R212I) 262 mutants. However, neither of these mutant proteins possessed sufficient catalytic activity in 263 vitro for kinetic analyses. These data showed that the primary effect of the mutations was to 264 significantly compromise the overall activity of FabH. 265
Gene expression in strains with mutant fabH. Expression of the fab genes in S. aureus 266 is regulated by the FapR transcription factor (44-47). In S. aureus, the fabH and fabF genes are 267
organized into an operon that is tightly controlled by FapR (44-46). FapR is a feed-forward 268
regulator that detects changes in the FASII precursor, malonyl-CoA and depresses the fabHF 269 operon in response to the inhibition of the pathway (44). Therefore, we used qRT-PCR to 270 measure the transcript levels of fabH and fabF to determine if their expression levels were 271 elevated indicating a defect in FASII in vivo. Three mutant strains were analyzed, and in each 272 case fabH and fabF expression were significantly increased (Fig. 5) . The accD gene is not part 273 of the FapR regulon and was not altered in the fabH mutant strains. However, the increase in 274 fabH and fabF expression in the mutant strains was not as great as observed in strain CS34 275 (fapR) (Fig. 5) . This suggested that strain CS34 may be more resistant to the FabF inhibitors 276 due to the increased expression of FabF; however, the MIC for all three antibiotics was the 277 same in the fapR knockout strain as in its wild-type parent (platensimycin, 0.78 g/ml; platencin, 278 0.78 g/ml; and thiolactomycin, 25 g/ml). This observation was on the surface inconsistent 279 with the reports that the MIC for platensimycin and platencin was increased by overexpressing 280 fabF or decreased by expressing siRNA directed against fabF (6, 6, 15, 16). Also, FabB 281 overexpression increases thiolactomycin resistance in E. coli (27) . These data suggested that 282 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from resistance was simply related to the level of FabF expression. However, when fabF expression 283 was increased by inactivating the FapR repressor in strain CS34 (fapR), the strain did not 284 exhibit increased resistance to FabF-targeted antibiotics. The plasmid-driven expression of 285 FabH(G203S) in strain RN4220 (platensimycin MIC = 0.78 g/ml) did not alter the MIC for the 286
FabF antibiotics showing that the FabH(G203S) was recessive rather than a dominant mutation. 287
The expression of wild-type FabH using the same plasmid system did not alter the MIC in the 288 wild-type strain (platensimycin MIC = 0.78 g/ml), but when introduced into strain MWF55 289 (FabH(G203S)) reduced the MIC for the FabF antibiotics to wild-type levels (platensimycin MIC 290 = 0.78 g/ml). Thus, restoring FabH activity to the fabH mutant strains returned their sensitivity 291 to platensimycin to the low MIC characteristic of wild-type strains. 292
Independent manipulation of FabH and FabF levels. Constructs were designed to 293
selectively manipulate the expression of fabH and fabF, and the protein levels were monitored 294 by western blot analysis. The strain used for these experiments was SA178R1, which had a 295 slightly lower MIC for platensimycin compared to strain RN4220. The large elevation in fabHF 296 mRNA in the fapR strain (Fig. 5) resulted in a less substantial increase in both FabH (1.7-fold) 297
and FabF (1.6-fold) protein levels (Fig. 6A ). This coordinate increase in both proteins did not 298 affect the susceptibility to platensimycin (Fig. 6B) . Super-repression of the fabHF operon by 299 elevated FapR expression resulted in a 50% decrease in both FabH and FabF proteins (Fig.  300   6A) . The lower levels of these key condensing enzymes resulted in a significant IPTG-301 dependent growth defect, but did not change the MIC for platensimycin (Fig. 6B) . Substantially 302 increased FabH protein by expression of pfabH (3.5-fold) (Fig. 6A) did not alter the 303 platensimycin MIC (Fig. 6B) . Increasing fabF expression using pfabF resulted in a 4-fold 304 increase in resistance that correlated with a substantial increase (3.2-fold) in FabF protein (Fig.  305   6) . The experiments with the pfabHF plasmid were complicated by the presence of an internal 306 promoter in the fabHF operon that led to a 2.7-fold increase in the levels of FabF and a 16-fold 307 on November 3, 2017 by guest http://aac.asm.org/ Downloaded from increase in the MIC for platensimycin in the absence of inducer (Fig. 6) . The expression of the 308 fabH siRNA construct (pfabH-AS) decreased FabH protein by 50%, but had negligible effect on 309
FabF levels (Fig. 6A) . The expression of this antisense construct might be expected to 310 decrease both FabH and FabF equally because they are in the same operon; however, the 311 existence of a fabF promoter within the fabHF operon means that FabF was not as affected as 312
FabH when expression of the antisense construct was induced (Fig. 6A) . This small decrease 313 in the FabH:FabF ratio resulted in a 4-fold increase in the MIC (Fig. 6B) . The expression of the 314 pfabF-AS antisense construct decreased the levels of both FabH and FabF by 50% (Fig. 6A ) 315 and led to a 2-fold decrease in the platensimycin MIC (Fig. 6B) . Taken together, these data 316 were consistent with the FabH:FabF protein ratio as a key determinant of a strain's sensitivity to 317 platensimycin. 318
319
DISCUSSION 320
This work identifies a unique mechanism for genetically acquired resistance to the natural 321 product FabF inhibitors platensimycin, platencin and thiolactomycin in S. aureus. At the onset, 322
we anticipated detecting specific mutations in the fabF gene that would render the mutant FabF 323 enzymes refractory to inhibition by the drug while retaining some activity. These mutations 324 would be specific for the antibiotic used for selection because each antibiotic has a different 325 mode of binding to the acyl-enzyme intermediate. However, every resistant clone isolated had 326 a wild-type fabF gene, and instead each harbored one of several different mutations in the fabH 327 gene. Regardless of which antibiotic was used for selection, the resulting mutant strains 328 acquired resistance to all three antibiotics (platensimycin, platencin and thiolactomycin). The 329 fabH mutants give rise to defective enzymes based on in vitro biochemical analysis, in vivo 330 gene expression profiles and impaired cell growth that is rescued by exogenous fatty acids. 
